Objective: Vascular endothelial growth factor (VEGF) has been suggested to enhance glucose transport across the blood-brain barrier, thereby increasing brain glucose supply. Increased brain glucose concentration is known to suppress food intake and to decrease body mass via action on hypothalamic regulation centers. Based on the crucial role of VEGF on brain glucose supply, we hypothesized that higher VEGF concentrations are associated with lower food intake and body mass in humans. Methods: Intending to investigate subjects with high variance of blood glucose, we examined patients with type 2 diabetes mellitus. Our hypothesis was tested in a population-based cohort of 190 subjects with type 2 diabetes. Plasma VEGF levels in conjunction with other parameters known to modulate food intake were measured and subsequently correlated with food intake patterns at a breakfast buffet as well as with body mass. Results: We found that subjects with higher concentrations of plasma VEGF had 17% less carbohydrate intake (P ¼ 0.003) and 4.8% lower body mass (P ¼ 0.017) than those with lower VEGF concentrations. Intake of protein and fat did not correlate with VEGF concentrations. These associations of plasma VEGF were confirmed in multiple linear regression analyses controlling for several parameters interacting with food intake. Conclusion: We conclude that high plasma VEGF concentrations are associated with less carbohydrate intake and lower body mass in type 2 diabetes. The role VEGF plays in facilitating glucose access to the brain represents a new aspect of food intake regulation and energy homeostasis, with relevance for diseases with body mass disturbances.
Introduction
High caloric food intake and a sedentary life style have caused a continuous rise in the prevalence of type 2 diabetes and obesity over the past 25 years. 1 Remarkably, patients with type 2 diabetes often fail to reduce food intake and body mass over time. Although various studies have already focused on the problem, the pathogenesis of food intake dysregulation remains obscure, pointing to mostly noneffective dietary strategies. One of the factors basically involved in food intake regulation is glucose supply of the brain. 2, 3 Increased brain glucose concentration is known to suppress food intake and thereby decrease body mass via action on hypothalamic regulation centers. 4, 5 Blood glucose must be transported by carrier mechanisms across the blood-brain barrier (BBB) to become available for brain metabolism. The carrier protein specific for glucose transport across the BBB is the glucose transporter (GLUT) 1. 6 In turn, GLUT 1 is regulated by various factors one of which is the polypeptide vascular endothelial growth factor (VEGF), 7, 8 a potent regulator of blood vessel function. 9, 10 Vascular endothelial growth factor has been demonstrated to increase GLUT 1 expression 7, 11 as well as its translocation from the cytosol to the plasma membrane surface. 8 In addition, VEGF induces endothelial fenestration and increases vascular permeability of the BBB. 12 Both mechanisms, rise of GLUT 1 and of BBB permeability, can enhance brain glucose supply. Recently, Dantz et al. 13 have shown that circulating VEGF strongly increases during hypoglycemia, and this increase is correlated with the maintenance of neurocognitive performance pointing to an important role of VEGF in the energy supply of the brain.
Considering VEGF's effects on BBB function and GLUT 1-related glucose transport, we hypothesized that plasma VEGF concentration correlates with food intake patterns and body mass. As brain glucose supply depends on blood glucose, we examined subjects with type 2 diabetes mellitus representing a cohort with a large natural variance of blood glucose. We measured plasma VEGF in conjunction with several other factors potentially influencing food intake and body mass such as concentrations of blood glucose, insulin, leptin and cortisol before a breakfast buffet.
Subjects and methods

Participants
The patients with diabetes mellitus were recruited in a survey among all gainfully employed insurants of the Landesversicherungsanstalt Schleswig-Holstein (regional pension fund for blue collar workers, n ¼ 12 430) in Luebeck and suburbs, Germany. The target population comprised men and women born in 1939-1958. All subjects with confirmed diabetes mellitus (n ¼ 346) 14 were invited for a medical examination and 216 patients participated. Among these, 190 had type 2 diabetes (male to female ratio 140/50), which was confirmed by two diabetologists. Each participant gave written informed consent and the local ethics committee approved the study. The study population was characterized as follows: mean age, 53.975.2 years; mean body mass, 93.071.2 kg; mean body mass index (BMI), 31.370.4 kg/m 2 ; mean glycosylated hemoglobin, 7.770.1%. The population was classified depending on stepwise pharmacological diabetes treatment scored from 1 to 4: (1) diet, 24% of subjects; (2) oral antidiabetic drugs, 52% of subjects; (3) insulin treatment, 12% of subjects; (4) combination of insulin and oral antidiabetic drugs, 12% of subjects.
Structured medical interview and examination
The examination began at 0800 after an overnight fast. Blood samples were taken for determination of plasma VEGF, blood glucose, glycosylated hemoglobin, corticotropin (ACTH), serum cortisol, leptin and insulin concentrations. Furthermore, urine samples were collected for measurement of urinary glucose. A breakfast buffet was offered to the volunteers, who were free to choose among a large variety of food. An examined diabetes assistant analyzed the consumed food for its amount of carbohydrate, protein and fat. After breakfast, a structured medical interview was performed, including diabetes-specific medical history and current use of medication. Eating behavior was assessed using the three-factor-eating-questionnaire (German version: FEV; Fragebogen zum Everhalten 15 ). The evaluation of this questionnaire results in three ordinal scaled factors describing cognitive control of eating behavior (FEV1), possibility of interference with eating control (FEV2) and interfering hunger feelings (FEV3). During the subsequent physical examination, we assessed body measures including height, body mass and the resulting BMI.
Assays
All blood samples were immediately centrifuged and the supernatants stored at À241C until assay. The concentration of VEGF 165 in plasma samples was measured in duplicate by a sandwich-type enzyme-linked immunoassay (Quantikine; R&D Systems, Minneapolis, MN, USA). The intra-and interassay coefficients of variation (CV) were o5 and o7.5%, respectively; the lower detection limit was 9 pg/ml. Enzyme-linked immunosorbent assays were used for the determination of serum insulin (ELISA, DAKO Ltd, Cambridgeshire, UK; interassay CVo8.9%, intra-assay CVo7.5%). Plasma glucose was measured in duplicate using the glucose oxidase method (glucose analyzer, Beckman Coulter Inc., Instruments GmbH, Munich, Germany; intraand interassay CVo1.8 and o2.6%, respectively). Cortisol serum concentrations were determined by electrochemiluminescence immunoassay in conjunction with the Elecsys 2010 (Roche Molecular Biochemical Diagnostics, Mannheim, Germany; intraassay CVo1.3%; interassay CVo1.5%) and plasma ACTH concentrations were measured by immunoluminometric two-step assay (Lumitest ACTH, Brahms Diagnostics, Berlin, Germany; intra-assay CVo6.0%; interassay CVo8.0%). Leptin serum concentrations were analyzed by a highly sensitive radioimmuno (Linco Research Inc., St Charles, MO, USA; intra-assay CVo3.9% and interassay CVo4.7%). Urinary glucose and glycosylated hemoglobin were measured by routine clinical methods.
Statistical analysis
Statistical analysis was performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA). As plasma VEGF concentrations (z-value: 2.0; Po0.01) as well as urinary glucose concentrations (z-value: 3.4; Po0.01) were not normally distributed, we applied a median (31.0 pg/ml) split of plasma VEGF concentrations and transformed the variable 'urinary glucose' into the binary variable 'glucosuria' as positive value for further statistical analysis. Glucosuria was defined as urinary glucose 410 g/l.
First, we applied a bivariate correlation analysis with special focus on food intake patterns in relation to potentially influencing parameters, including VEGF, blood glucose, leptin, cortisol and glucosuria. Further, we used multiple regression analyses to confirm the observed correlations controlling for potentially influencing parameters: gender, VEGF, BMI, blood glucose, glucosuria, cortisol, insulin, leptin, type of diabetes treatment and variables of the eating behavior questionnaire. Regression analyses were performed between potentially influencing parameters and amount of carbohydrate, protein, fat intake and body VEGF and carbohydrate intake in diabetes C Hubold et al mass. The significant variables were assessed by stepwise forward selection.
We divided the study population according to the median value of plasma VEGF (31.0 pg/ml) and compared the carbohydrate intake between subgroups for illustrative reasons in an analysis of variance (ANOVA). We adjusted the ANOVA models for potentially interacting parameters: gender, BMI, insulin, eating behavior variables, glucosuria, blood glucose, leptin and cortisol concentration. The same parameters (except BMI) were used as covariates in an ANOVA for evaluation if patients with different VEGF concentrations differ in body mass. All results are presented as means7s.e.m. A P-value less than 0.05 was considered significant.
Results
The crucial finding was that plasma VEGF concentrations were negatively associated with carbohydrate intake in patients with type 2 diabetes. Patients with higher plasma VEGF (X31.0 pg/ml) had 17% less carbohydrate intake than those with lower concentrations (32.371.3 vs 38.071.3 g; P ¼ 0.003). Furthermore, higher plasma VEGF concentrations were associated with a 4.8% lower body mass (90.871.3 vs 95.271.3 kg; P ¼ 0.017).
In the multiple linear regression model, concentrations of VEGF, blood glucose and cortisol as well as female gender were related to lower carbohydrate intake, whereas glucosuria was related to higher carbohydrate intake ( Table 1) . The model also controlled for age, BMI, insulin, leptin, stepwise pharmacological diabetes treatment and eating behavior (FEV1-3). However, these parameters were not significantly associated with carbohydrate intake and thus were not selected by stepwise forward selection. Leptin was negatively correlated with carbohydrate intake only when gender was removed as controlling parameter (P ¼ 0.004). In contrast to carbohydrate intake (Table 1) , VEGF was not associated with protein, fat and total food intake ( Table 2) . Further, body mass was negatively associated with VEGF concentrations in multiple linear regression analysis (Table 3 ). Blood glucose, leptin and FEV2 correlated positively with body mass (Table 3) .
The univariate ANOVA for population subgroups split by median value confirmed that the patients with higher VEGF concentrations had less carbohydrate intake than those with lower concentrations (P ¼ 0.003; Figure 1a) . Also, ANOVA revealed that higher VEGF concentrations were associated with lower body mass (P ¼ 0.017; Figure 1b ).
Discussion
Our data from a population-based cohort show that in patients with type 2 diabetes, high plasma VEGF concentrations correlate with low carbohydrate intake, whereas no such association was observed between plasma VEGF and fat, protein and total food intake. Moreover, body mass was lower in patients with high VEGF concentrations. To our knowledge, the role of VEGF in food intake has never been the target of investigations before.
The selective association of plasma VEGF concentrations with carbohydrate intake supports a recently proposed role of VEGF in facilitating glucose passage across the BBB. 7, 13 The control of brain glucose is of utmost importance and VEGF and carbohydrate intake in diabetes C Hubold et al involves numerous neuroendocrine pathways. Activation of these neuroendocrine pathways depends on a widely distributed neural network that monitors energy derived from brain glucose metabolism in the hypothalamus, the brainstem and the cortex. 3, 16, 17 Via this network, brain glucose modulates the neuroendocrine pathway of food intake regulation in a feedback control manner. A deficiency in brain glucose induces expression of orexigenic neuropeptides 18 and causes glucoprivic feeding, 19 frequently associated with a preference for sweet taste and carbohydrates. 20 This carbohydrate preference relates to the fact that carbohydrate intake increases brain glucose supply to a greater extent than protein intake or fat intake. High brain glucose concentrations suppress food intake and body mass consistent with a negative feedback regulation. 4, 5 Pathways that allocate glucose into the brain, thereby increasing brain glucose feedback, should indirectly suppress food intake. 3 Vascular endothelial growth factor and sympathoadrenal activity may jointly contribute to such glucose allocation. 2 This view is in line with the negative correlation between plasma VEGF concentrations and carbohydrate intake in our study, reflecting an enhancing influence of VEGF on the negative brain glucose feedback. The second important finding was that body mass was lower in patients with high VEGF concentrations. Consistent with this finding, Proescholdt et al. 21 found in an intervention study that prolonged administration of VEGF in encephalitis rats promotes body mass loss. As type 2 diabetes is commonly associated with an increase in body mass, the correlation of low body mass and high VEGF may be of high clinical importance. Notably, plasma VEGF concentrations before a breakfast meal were more strongly associated with carbohydrate intake than leptin and insulin, two well-known appetite-regulating hormones. 22 In Addition to VEGF, blood glucose and cortisol concentrations, were negatively but independently correlated with carbohydrate intake. The association of high blood glucose concentration with lower food intake is consistent with the results of previous intervention studies 23 and supports the view of a glucostatic component in food intake regulation. 24 The negative correlation between cortisol and food intake seems to be controversial at first glance. Cortisol concentrations in our patients strongly correlated with ACTH concentrations, indicating central activation of the hypothalamo-pituitary-adrenocortical (HPA) axis. In contrast to exogenously administered glucocorticoids, central activation of HPA axis seems to reduce food intake and body mass, in such a way as in typical depression 25 and during intracerebroventricular infusion of corticotropinreleasing hormone. 26 Subjects with glucosuria showed high carbohydrate intake. This association may be linked to the characteristic symptoms of poorly controlled diabetes: glucosuria, polyphagia and polydipsia. Subjects with glucosuria, who lose large amounts of glucose and related energy by urine excretion, increase food intake for compensation. 27 The origin of circulating VEGF in our study is uncertain. Previous findings indicate that the hypothalamus, pituitary and adrenal gland participate in VEGF production and secretion. 28, 29 Circulating VEGF binds to high affine receptors that are widely distributed throughout the vasculature system. 10 The highest density of VEGF binding sites has been demonstrated in the vessels of the brain. 30 Nevertheless, for the moment, there is still little experimental evidence that VEGF directly increases glucose transport in endothelial cells of adult brain capillaries. Support for the proposed role of VEGF in the energy supply of the brain derives from findings demonstrating that VEGF directly enhances GLUT 1-related glucose transport in endothelial cells of the blood-retina barrier, 8 which resembles the BBB. However, there exist several potential candidates other than VEGF that can alter glucose transport at the BBB, such as glutamate, angiotensin-II and histamine. VEGF and carbohydrate intake in diabetes C Hubold et al A limitation of our study is that the cross-sectional design does not allow causal conclusions or conclusions about longterm associations between VEGF and food intake pattern. Therefore, we have to rely on causal interference shown in intervention studies 21 and propose further longitudinal studies in humans. We have only examined patients with type 2 diabetes, and further testing in healthy control persons is required for generalizing our results. However, the role of VEGF is of particular importance in type 2 diabetes, as recent treatment approaches have used both VEGF and VEGF antagonists to improve sequelae of the disease such as diabetic neuropathy or retinal neovascularization. [32] [33] [34] [35] Such treatment strategies should reconsider possible side effects on energy metabolism. Our findings that plasma VEGF is associated with low carbohydrate intake in patients with type 2 diabetes points to a new aspect in food intake regulation and energy homeostasis, which may be of relevance also for other diseases with disturbed food intake regulation.
